5×105 tumor cells were injected s.c. into mice, which formed tumors with a 1.5-cm diameter within 2–3 weeks of injection. Lipofermata was administrated s.c. at dose of 2 mg/kg twice per day. As a control, mice were treated with vehicle alone (DMSO + 30% v/v Kolliphor). Treatments with lipofermata started 8–10 days after tumors injections. CSF1R antibody (BioXcell, 300 μg/mouse) was administered every other day starting next day after tumor injection and continued until the mice were sacrificed. PD-1 antibody (clone RMP1–14, BioXcell, 200 μg/mouse) was administered twice a week started 10–12 days after tumor injection. CTLA4-IgG2a (BioXcell, 200 μg/mouse) was administered at day 7 and day 11.
Pd 1 antibody clone rmp1 14
Manufactured by BioXCell
Sourced in United States
The PD-1 antibody (clone RMP1-14) is a laboratory reagent used in research applications. It binds to the programmed cell death 1 (PD-1) protein, which is a key regulator of the immune system. This antibody can be utilized in various immunological assays and experiments to study the role of PD-1 in biological processes.
Automatically generated - may contain errors
Lab products found in correlation
Csf1r antibody, by BioXCell (2 mentions)
Ctla4 igg2a, by BioXCell (2 mentions)
Cd45.1 pe, by Thermo Fisher Scientific (1 mentions)
F4 80 percp cy5, by BioLegend (1 mentions)
Cd11b bv650, by BioLegend (1 mentions)
Pd l1 pe, by BioLegend (1 mentions)
Cd4 bv421, by BioLegend (1 mentions)
Pd1 bv605, by BD (1 mentions)
Cd90.1 fitc, by Thermo Fisher Scientific (1 mentions)
Cd45.1 apc, by Thermo Fisher Scientific (1 mentions)
Cd45.2 alexa700, by Thermo Fisher Scientific (1 mentions)
Cd8α percp cy5, by Thermo Fisher Scientific (1 mentions)
Cd103 apc, by Thermo Fisher Scientific (1 mentions)
Cd24 apc cy7, by Thermo Fisher Scientific (1 mentions)
Cd44 apcy7, by Thermo Fisher Scientific (1 mentions)
Cd90.2 alexa 700, by BioLegend (1 mentions)
Mhcii bv421, by BioLegend (1 mentions)
Cd8α pe texas red, by Thermo Fisher Scientific (1 mentions)
Ly6c bv711, by BioLegend (1 mentions)
Cd3e pe, by BD (1 mentions)
3 protocols using pd 1 antibody clone rmp1 14
1
Tumor Immunotherapy Protocol in Mice
2
Multiparametric Flow Cytometry Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Flow-cytometry antibodies included CD3e-PE, PD1-BV605, CD45-BV786 (BD-Biosciences), CD90.1-FITC, CD62L-PECy7, CD45.1-APC, CD45.1-PE (eBioscience), CD45.2-Alexa700, CD-8α-Percp-Cy5.5, CD4-FITC, CD103-APC, CD24-APCcy7 (Invitrogen), CD44-APCy7, CD4-BV421, F4/80-PercpCy5.5, CD39-PECy7, PDL1-PE, CD90.2-Alexa 700, MHCII-BV421, CD11b-BV650, Ly6C-BV711 (Biolegend), CD8α-PE-Texas-red (Life Technologies, Carlsbad, CA, USA). Blocking PD-1 antibody (clone RMP1-14, BioXCell, Branford, CT, USA) was administered systemically by intraperitoneal injections of 250 μg [41 (link)]. Blocking anti-CD40L (clone MR1, BioXCell) was administered systemically by intraperitoneal injections of 250 μg [19 (link)].
3
Tumor Immunotherapy Protocol in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
5×105 tumor cells were injected s.c. into mice, which formed tumors with a 1.5-cm diameter within 2–3 weeks of injection. Lipofermata was administrated s.c. at dose of 2 mg/kg twice per day. As a control, mice were treated with vehicle alone (DMSO + 30% v/v Kolliphor). Treatments with lipofermata started 8–10 days after tumors injections. CSF1R antibody (BioXcell, 300 μg/mouse) was administered every other day starting next day after tumor injection and continued until the mice were sacrificed. PD-1 antibody (clone RMP1–14, BioXcell, 200 μg/mouse) was administered twice a week started 10–12 days after tumor injection. CTLA4-IgG2a (BioXcell, 200 μg/mouse) was administered at day 7 and day 11.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!